PLN: A Drug Target / Disease Biomarker (G5350)

Target Name: PLN

NCBI ID: G5350

Content of Review Report on PLN Target / Biomarker

PLN

PLN: A Drug Target / Disease Biomarker

PLN, short for Plasma Levels of Neurotransmitters, refers to the levels of certain neurotransmitters found in the bloodstream. These neurotransmitters are responsible for transmitting signals between the brain and the rest of the body. They are a crucial aspect of brain function and play a key role in the development and treatment of various neurological disorders. As a drug target or biomarker, PLN has a significant impact on the treatment options available for these disorders.

PLN has been identified as a potential drug target for a number of neurological disorders, including depression, anxiety, and neurodegenerative diseases. Studies have shown that changes in PLN levels can accurately predict the response to antidepressants and other medications used to treat these disorders. Additionally, PLN levels have been found to be lower in individuals with major depressive disorder (MDD) and anxiety than in those without the disorder. This suggests that PLN may be a useful biomarker for the diagnosis and treatment of MDD and anxiety.

Another promising application of PLN as a drug target is its potential role in the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a range of symptoms including memory loss, movement disorders, and cognitive decline. PLN has been shown to be lower in individuals with Alzheimer's disease and Parkinson's disease compared to healthy individuals. This suggests that PLN may be a potential target for the development of new treatments for these conditions.

PLN has also been identified as a potential biomarker for certain psychiatric disorders, such as schizophrenia and Bipolar disorder. Studies have shown that changes in PLN levels can accurately predict the response to antipsychotic medications used to treat these disorders. Additionally, PLN levels have been found to be higher in individuals with schizophrenia and Bipolar disorder than in those without the disorder. This suggests that PLN may be a useful tool for the diagnosis and treatment of these disorders.

In addition to its potential role as a drug target and biomarker, PLN has also been shown to have a number of potential therapeutic benefits. For example, PLN has been shown to have anti-inflammatory properties and to protect brain cells from the effects of oxidative stress. This suggests that PLN may have potential as a therapeutic agent for the treatment of conditions such as multiple sclerosis and neuro-inflammatory disorders. Additionally, PLN has been shown to have a number of potential applications in regenerative medicine, as it has been shown to promote the growth and differentiation of brain cells.

Despite the potential benefits of PLN as a drug target and biomarker, there are also a number of challenges that must be overcome before it can be widely used. One of the major challenges is the difficulty of obtaining accurate and reliable PLN levels from blood samples. This is because PLN levels can be affected by a number of factors, including diet, stress, and certain medications. Additionally, there are concerns about the potential side effects of PLN, particularly in individuals with certain medical conditions.

Another challenge is the limited understanding of the underlying mechanisms responsible for the regulation of PLN levels. While research has identified a number of potential targets for PLN, it is not yet clear exactly how these targets are involved in the regulation of PLN levels. Further research is needed to fully understand the role of PLN in the brain and the potential therapeutic applications of PLN.

In conclusion, PLN is a promising drug target and biomarker with a number of potential therapeutic applications. While there are still many challenges that must be overcome, the potential benefits of PLN make it an important area of research for the development of new treatments for a wide range of neurological disorders.

Protein Name: Phospholamban

Functions: Reversibly inhibits the activity of ATP2A2 in cardiac sarcoplasmic reticulum by decreasing the apparent affinity of the ATPase for Ca(2+) (PubMed:28890335). Modulates the contractility of the heart muscle in response to physiological stimuli via its effects on ATP2A2. Modulates calcium re-uptake during muscle relaxation and plays an important role in calcium homeostasis in the heart muscle. The degree of ATP2A2 inhibition depends on the oligomeric state of PLN. ATP2A2 inhibition is alleviated by PLN phosphorylation. Controls intracellular Ca(2+) levels in elongated spermatids. May play a role in germ cell differentiation (By similarity)

The "PLN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets